26 March 2024 – Novo Nordisk A/S has announced its agreement to acquire Cardior Pharmaceuticals for up to $1 billion ($1.1 billion), marking a strategic move by the Danish pharmaceutical company to expand its presence in treatments for cardiovascular disease.
The acquisition, revealed on Monday, entails an upfront payment to Cardior, with additional payments contingent upon the achievement of specific milestones by the company.
Cardior Pharmaceuticals specializes in the development of therapies targeting microRNA, a class of molecules involved in regulating protein production within cells. Its leading potential treatment aims to counter abnormal levels of a specific microRNA, with the objective of enhancing long-term heart function. Currently, the compound is undergoing the second stage of patient trials, with promising prospects for addressing cardiovascular ailments.
Novo Nordisk’s focus on cardiovascular disease reflects its strategic pivot amid soaring global demand for its blockbuster drugs, Ozempic and Wegovy, used in treating obesity. The success of these drugs has propelled Novo Nordisk to become Europe’s most valuable business, prompting the company to reinvest part of its profits into expanding its portfolio of experimental medications.
In recent times, Novo Nordisk has increasingly directed its acquisitions towards cardiovascular disease, recognizing it as the leading cause of death worldwide. The acquisition of Cardior Pharmaceuticals marks the seventh instance where Novo has explicitly targeted this therapeutic area.
The expanded US approval for Wegovy, encompassing the reduction of heart attack and stroke risks, further underscores the significance of cardiovascular disease management in Novo Nordisk’s strategic vision. This alignment with Novo’s expertise in diabetes and obesity reinforces its commitment to addressing critical healthcare needs.
As Novo Nordisk continues to navigate the evolving landscape of pharmaceuticals, the acquisition of Cardior Pharmaceuticals signifies its dedication to advancing cardiovascular therapeutics and improving patient outcomes.
